Form 4: Disc Medicine Director Mona Ashiya Granted 10,000 Stock Options
Insider Transaction Report
Disc Medicine, Inc. Director Mona Ashiya has been granted 10,000 stock options with an exercise price of $50.86, subject to specific vesting conditions and an obligation to transfer the economic benefit to OrbiMed entities.
Summary
- Mona Ashiya, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
- The transaction date for this grant was June 11, 2025.
- The exercise price for these stock options is $50.86 per share.
- The options are set to expire on June 10, 2035.
- The shares underlying the option will vest upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date, contingent on Ms. Ashiya's continued service.
- Ms. Ashiya is obligated to transfer any securities issued from these options, or their economic benefit, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will then provide them to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is generally viewed as a positive sign of alignment and commitment, although the specific transfer obligation to OrbiMed adds a unique structural element.
Positives
- The grant of stock options to a director can align their interests with those of shareholders, incentivizing long-term company performance.
- The transaction indicates continued commitment of a key director to the company's future.
Negatives
- The exercise of these options in the future could lead to a minor dilution of existing shareholder equity.
Future Outlook
NA
Industry Context
This Form 4 filing is a standard disclosure for insider transactions in publicly traded companies, common in the biotechnology and pharmaceutical sectors like Disc Medicine. Stock option grants are a typical component of executive and director compensation packages, designed to align leadership incentives with shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Structure Detail | Mona Ashiya, a Director, is obligated to transfer the economic benefit of her stock options to specific OrbiMed entities. This indicates a structured arrangement for her compensation, likely tied to her role or affiliation with OrbiMed. | 06/11/2025 | This arrangement clarifies the ultimate beneficial ownership of the granted options, indicating that the economic benefit accrues to OrbiMed Private Investments funds rather than directly to the individual director. It highlights a specific governance mechanism for director compensation when the director is affiliated with a major investor. |
Related Party Transactions
- Mona Ashiya, a Director of Disc Medicine, is obligated to transfer the economic benefit of her 10,000 stock options to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will then provide them to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP. This constitutes a related party transaction given Ms. Ashiya's likely affiliation with OrbiMed.
Stakeholder Impact
- Shareholders: Potential minor dilution upon option exercise, but also potential alignment of a key director's interests (via OrbiMed) with long-term company performance.
- OrbiMed Entities: Directly benefit from the economic value of the granted options, reinforcing their investment position in Disc Medicine.
Next Steps
- The stock options will vest upon the earlier of Disc Medicine's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026), subject to Mona Ashiya's continued service.
Key Dates
| Date | Description |
|---|---|
| 06/11/2025 | Date of earliest transaction (stock option grant date). |
| 06/13/2025 | Date the Form 4 was signed and filed. |
| 06/10/2035 | Expiration date of the stock options. |
| 2026 | Approximate year of the Company's annual meeting, which is a potential vesting trigger for the options. |
Keywords
Disc Medicine, IRON, Stock Options, Insider Trading, SEC Form 4, Director Compensation, Equity Grant, OrbiMed
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.